Foundayo (Orforglipron) Cost 2026: What the New Pill Actually Costs
Key Takeaways
- Foundayo (orforglipron) was FDA-approved on April 1, 2026 — the first oral non-peptide GLP-1 for weight loss
- Self-pay pricing starts at $149/month for the lowest dose through manufacturer channels and telehealth partners
- Higher maintenance doses cost $199–$349/month depending on dose and platform
- Medicare GLP-1 Bridge covers Foundayo at $50/month for qualifying beneficiaries
- Key advantage over Wegovy pill: no fasting required — can be taken with or without food, any time of day
Foundayo became the first oral non-peptide GLP-1 receptor agonist approved for weight loss when the FDA cleared it on April 1, 2026. Made by Eli Lilly, it uses orforglipron — a small-molecule drug that works on the GLP-1 receptor like semaglutide and tirzepatide but is chemically distinct. That molecular difference is why Foundayo has no food or water restrictions, doesn't require fasting, and is stable at room temperature without refrigeration.
It's also priced to compete directly with the Wegovy pill. Here's what Foundayo actually costs across every access pathway in 2026.
Foundayo Dose-by-Dose Pricing
Foundayo is taken orally once daily. The prescribing information includes a titration schedule that starts at a low dose and increases approximately monthly until a maintenance dose is reached. Here's what each step costs:
| Dose | Self-Pay (Manufacturer) | With Insurance + Savings Card | Medicare Bridge |
|---|---|---|---|
| Starting dose | $149/mo | $25/mo | $50/mo |
| Mid-titration | $199/mo | $25/mo | $50/mo |
| Maintenance dose | $299–$349/mo | $25/mo | $50/mo |
Self-pay pricing via telehealth partners and manufacturer channels. Exact dose strengths and final titration schedule per manufacturer labeling. Verified July 2026.
Eli Lilly priced Foundayo to match the Wegovy pill's entry point ($149/month) and undercut it at maintenance doses. This appears to be a deliberate competitive play — Lilly already prices Zepbound aggressively against Wegovy via LillyDirect, and Foundayo extends that strategy into the oral GLP-1 category.
Foundayo vs. Wegovy Pill: Price Comparison
These are the two FDA-approved oral GLP-1 options for weight loss in 2026. Here's how they compare on cost:
| Factor | Foundayo (Orforglipron) | Wegovy Pill (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Molecule type | Non-peptide (small molecule) | Peptide |
| Starting dose self-pay | $149/mo | $149/mo |
| Maintenance dose self-pay | $299–$349/mo | $299/mo |
| Insurance + savings card | $25/mo | $25/mo |
| Medicare Bridge | $50/mo | $50/mo |
| Fasting required? | No | Yes — 30-min empty stomach |
| Take with food? | Yes, any time | No — water only |
| Cold storage? | No | No |
| Dosing frequency | Once daily | Once daily |
| FDA approval date | April 1, 2026 | January 2026 (weight loss) |
Why the "No Fasting" Advantage Matters
On paper, pricing between Foundayo and the Wegovy pill is nearly identical. The meaningful difference is the fasting requirement — or lack of one.
Oral semaglutide (Wegovy pill, Rybelsus) must be taken on an empty stomach with no more than 4 ounces of plain water. You then must wait at least 30 minutes before eating, drinking anything else, or taking other medications. This is because semaglutide is a peptide that degrades in the stomach unless protected by a specific absorption enhancer (SNAC) that requires fasting conditions to work.
Orforglipron (Foundayo) doesn't need this. As a non-peptide molecule, it's absorbed through the GI tract regardless of food status. You can take it with breakfast, after dinner, or whenever is convenient — and it won't interact with other morning medications.
For people who take blood pressure meds, thyroid medication, or other pills first thing in the morning, this is a genuine practical advantage.
Medicare and Insurance Access
Foundayo is included in the Medicare GLP-1 Bridge program at $50/month for qualifying beneficiaries. The same BMI-based eligibility criteria apply as for Wegovy and Zepbound:
- BMI ≥ 35 (no additional conditions required)
- BMI 30–34.99 with weight-related comorbidity
- BMI 27–29.99 with documented prediabetes, stroke history, heart attack history, or symptomatic PAD
For commercial insurance, Foundayo is still relatively new. Coverage determinations are in progress at many plans. Eli Lilly offers a savings card that can bring the copay to $25/month for commercially insured patients with coverage — and caps costs at $149–$349/month for those whose plans don't cover it.
Compounded Alternatives at Lower Price Points
There is no compounded orforglipron — the molecule is too new and patent-protected. However, compounded semaglutide (injectable and oral formulations) is available at lower price points from telehealth providers:
Injectable
Compounded medications are prepared by pharmacies and are not FDA-approved. They have not been evaluated for safety, efficacy, or manufacturing quality by the FDA.
Check Current Pricing →Paid link · We may earn a commission
Injectable semaglutide
Compounded medications are prepared by pharmacies and are not FDA-approved. They have not been evaluated for safety, efficacy, or manufacturing quality by the FDA.
Check Current Pricing →Paid link · We may earn a commission
Injectable + oral
Compounded medications are prepared by pharmacies and are not FDA-approved. They have not been evaluated for safety, efficacy, or manufacturing quality by the FDA.
Check Current Pricing →Paid link · We may earn a commission
Is Foundayo Worth the Price?
At matched price points with the Wegovy pill ($149/month entry, $299/month maintenance), the decision between Foundayo and oral Wegovy comes down to the fasting trade-off and clinical data maturity.
Choose Foundayo if:
- You take other morning medications and can't manage the 30-minute fasting window
- You want maximum dosing flexibility (take it with meals, any time of day)
- You prefer a Lilly product and want to stay in their ecosystem (Zepbound + Foundayo)
Choose the Wegovy pill if:
- You're comfortable with the fasting requirement and already manage it easily
- You want the longer clinical track record of semaglutide
- Your insurance specifically covers Wegovy but not yet Foundayo
Foundayo enters the market at pricing designed to match the Wegovy pill dollar-for-dollar while offering a significant convenience advantage: no fasting, no food restrictions, no timing constraints. At $149/month starting and $50/month through Medicare, it's one of the most accessible FDA-approved GLP-1 options available in 2026. If your insurance doesn't cover it yet, that's the main reason to wait — otherwise, it's a strong option at a competitive price.
Prices verified as of July 15, 2026. Foundayo was FDA-approved April 1, 2026. Insurance coverage is still being established at many plans — check with your insurer for current formulary status. This is not medical advice.